The thesis

TG Therapeutics is a commercial-stage biopharmaceutical company out of New York, and its numbers already look like a profitable enterprise rather than a research story. Revenue grew 70.3% year over year, gross margin is 82.4%, and net margin is 55.2% at a 21.8x multiple. The Decifer score of 68 is high, and the active risk-off rotation treats the name as a direct beneficiary, adding meaningful conviction on top of a BUY consensus. The tension the market misses: analysts rate it a buy for its own story while the macro tape independently rotates capital into exactly this sector, and those two forces are rarely priced at once.

Why now

A risk-off rotation is currently underway and the macro signal flags TG Therapeutics as a direct beneficiary with strong evidence. Seventy percent revenue growth with a 55.2% net margin gives rotating capital a profitable destination rather than a speculative one.

What to watch

Quarterly revenue trajectory against the 70.3% growth rate and whether net margin holds near 55.2% as the commercial base scales. Evidence of continued fund flows into healthcare and biotech names through the next one to three quarters, confirming the rotation rather than a brief flush.

Key risks

The bull case assumes the rotation persists; if risk appetite returns to offensive sectors, the macro tailwind reverses and the name loses its defensive bid. A 21.8x multiple on a biotech leaves little room for a commercial or clinical setback in ublituximab or the broader pipeline. Consensus already says BUY, so much of the good news may be priced before the rotation fully plays out.

Theme exposure

Upcoming catalysts